论文部分内容阅读
目的:评价甲泼尼龙剂量递减疗法治疗小儿患者重症过敏性紫癜的临床疗效。方法:选取2014年4月—2016年6月期间收治的小儿重症过敏性紫癜患儿75例,将其随机分为观察组(38例)和对照组(37例);对照组患儿给予甲泼尼龙常规剂量治疗,观察组患者给予甲泼尼龙剂量递减疗法治疗,比较两组患儿用药后的症状改善时间、不良反应的发生率和住院时间,以及治疗的总有效率。结果:观察组患儿用药后皮疹消退时间、腹痛与关节症状缓解时间以及肾损伤恢复时间、住院时间均明显短于对照组(P<0.05),不良反应的发生率明显优于对照组(P<0.05),治疗后的总有效率高于对照组(P<0.05)。结论:甲泼尼龙剂量递减疗法用于治疗小儿患患者重症过敏性紫癜的临床疗效较佳,不良反应的发生率低,缩短了其症状复常时间和住院时间。
Objective: To evaluate the clinical efficacy of methylprednisolone dose-reduction therapy in the treatment of severe allergic purpura in children. Methods: Seventy-five children with severe Henoch-Schonlein purpura were enrolled in this study. The children were randomly divided into the observation group (38 cases) and the control group (37 cases). The children in the control group Prednisolone conventional dose treatment, observation group patients given methylprednisolone dose-reduction therapy, the two groups of children medication symptoms improvement time, the incidence of adverse reactions and hospital stay, and the total effective rate of treatment. Results: The children in the observation group had significantly shorter rash subsidence time, abdominal pain and joint symptom relief time, recovery time of renal injury and length of hospital stay than those in the control group (P0.05). The incidence of adverse reactions in the observation group was significantly higher than that in the control group (P <0.05). The total effective rate after treatment was higher than that of the control group (P <0.05). CONCLUSION: Methylprednisolone dose-reduction therapy is effective in the treatment of severe Henoch-Schonlein purpura in children. The incidence of adverse reactions is low, and the symptom recovery time and hospital stay are shortened.